206 related articles for article (PubMed ID: 38580884)
1. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
Lü Y; Cho T; Mukherjee S; Suarez CF; Gonzalez-Foutel NS; Malik A; Martinez S; Dervovic D; Oh RH; Langille E; Al-Zahrani KN; Hoeg L; Lin ZY; Tsai R; Mbamalu G; Rotter V; Ashton-Prolla P; Moffat J; Chemes LB; Gingras AC; Oren M; Durocher D; Schramek D
Mol Syst Biol; 2024 Jun; 20(6):719-740. PubMed ID: 38580884
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
3. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
[TBL] [Abstract][Full Text] [Related]
5. 53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms.
Cuella-Martin R; Oliveira C; Lockstone HE; Snellenberg S; Grolmusova N; Chapman JR
Mol Cell; 2016 Oct; 64(1):51-64. PubMed ID: 27546791
[TBL] [Abstract][Full Text] [Related]
6. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
8. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
9. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
Dekkers JF; Whittle JR; Vaillant F; Chen HR; Dawson C; Liu K; Geurts MH; Herold MJ; Clevers H; Lindeman GJ; Visvader JE
J Natl Cancer Inst; 2020 May; 112(5):540-544. PubMed ID: 31589320
[TBL] [Abstract][Full Text] [Related]
10. TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
Epping MT; Meijer LA; Krijgsman O; Bos JL; Pandolfi PP; Bernards R
Nat Cell Biol; 2011 Jan; 13(1):102-8. PubMed ID: 21170034
[TBL] [Abstract][Full Text] [Related]
11. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.
Ingallina E; Sorrentino G; Bertolio R; Lisek K; Zannini A; Azzolin L; Severino LU; Scaini D; Mano M; Mantovani F; Rosato A; Bicciato S; Piccolo S; Del Sal G
Nat Cell Biol; 2018 Jan; 20(1):28-35. PubMed ID: 29255172
[TBL] [Abstract][Full Text] [Related]
12. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
[TBL] [Abstract][Full Text] [Related]
13. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
Dhaka B; Sabarinathan R
BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
[TBL] [Abstract][Full Text] [Related]
14. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
15. A USP28-53BP1-p53-p21 signaling axis arrests growth after centrosome loss or prolonged mitosis.
Lambrus BG; Daggubati V; Uetake Y; Scott PM; Clutario KM; Sluder G; Holland AJ
J Cell Biol; 2016 Jul; 214(2):143-53. PubMed ID: 27432896
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
17. Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.
Müller I; Strozyk E; Schindler S; Beissert S; Oo HZ; Sauter T; Lucarelli P; Raeth S; Hausser A; Al Nakouzi N; Fazli L; Gleave ME; Liu H; Simon HU; Walczak H; Green DR; Bartek J; Daugaard M; Kulms D
Mol Cell; 2020 Mar; 77(5):970-984.e7. PubMed ID: 31982308
[TBL] [Abstract][Full Text] [Related]
18. P53 ICE CRIM mouse: a tool to generate mutant allelic series in somatic cells and germ lines for cancer studies.
Fan HH; Yu IS; Lin YH; Wang SY; Liaw YH; Chen PL; Yang TL; Lin SW; Chen YT
FASEB J; 2019 Apr; 33(4):5571-5584. PubMed ID: 30640520
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
[TBL] [Abstract][Full Text] [Related]
20. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
